<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508389</url>
  </required_header>
  <id_info>
    <org_study_id>GT-201</org_study_id>
    <nct_id>NCT02508389</nct_id>
  </id_info>
  <brief_title>A Study of GC4419 Protection Against Radiation Induced Oral Mucositis in Patients With Head &amp; Neck Cancer</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + IMRT for Locally Advanced Non-Metastatic SCC of the Oral Cavity/Oropharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Assistance Programs, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novella Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered
      prior to intensity-modulated radiation therapy (IMRT) protects against radiation induced
      oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic
      squamous cell carcinoma of the head and neck.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GT-201 is a randomized, double-blind, placebo-controlled, multi-center study conducted in
      the U.S. to evaluate GC4419 administered IV for the prevention of radiation induced oral
      mucositis in patients receiving cisplatin plus intensity-modulated radiation therapy for
      post-operative, or definitive treatment of locally advanced, non-metastatic squamous cell
      carcinoma of the head and neck, limited to the oral cavity or oropharynx. Patients will be
      randomized equally to 1 of 3 treatment arms:

      Arm A: 30 mg GC4419 per day (60 min IV infusion to complete within 60 minutes prior to
      IMRT), concurrent with daily fractions of IMRT (2.0 - 2.2 Gy) to a total of 60 - 72 Gy over
      approximately 7 weeks, plus cisplatin administered 80 - 100 mg/m2 once every three weeks for
      3 doses or 30 - 40 mg/m2 once weekly for 6-7 doses (investigator's choice).

      Arm B: 90 mg GC4419 per day (60 min IV infusion to complete within 60 minutes prior to
      IMRT), concurrent with daily fractions of IMRT (2.0 - 2.2 Gy) to a total of 60 - 72 Gy over
      approximately 7 weeks, plus cisplatin administered 80 - 100 mg/m2 once every three weeks for
      3 doses or 30 - 40 mg/m2 once weekly for 6-7 doses (investigator's choice).

      Arm C: Placebo daily (60 min IV infusion to complete within 60 minutes prior to IMRT),
      concurrent with daily fractions of IMRT (2.0 - 2.2 Gy) to a total of 60 - 72 Gy over
      approximately 7 weeks, plus cisplatin administered 80 - 100 mg/m2 once every three weeks for
      3 doses or 30 - 40 mg/m2 once weekly for 6-7 doses (investigator's choice).

      Planned radiation fields in all 3 arms must include at least two oral sites (buccal mucosa,
      floor of mouth, tongue, soft palate) with each site receiving a dose of at least 50 Gy.

      All patients will be assessed twice weekly for oral mucositis per WHO grading criteria until
      the completion of IMRT, and once weekly thereafter (if necessary) for 8 weeks, or until oral
      mucositis resolves to ≤ Grade 1.

      Approximately 200 total to ensure that roughly 60 patients per arm receive study drug and
      complete requirements for primary endpoint analysis, which is defined as patients receiving
      a minimum cumulative dose of 60 Gy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Duration of Radiation Induced Severe Oral Mucositis per WHO Criteria, Through a Minimum of 60 Gy IMRT Delivered to the Tumor</measure>
    <time_frame>Minimum of 60 Gy administered to tumor, approximately 30 IMRT fractions, which is estimated to be 6-7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the duration of severe OM, as assessed from the first determination of ≥ Grade 3 OM to the first instance of non-severe OM (≤ Grade 2), without a subsequent instance of ≥ Grade 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Low Dose vs. High Dose GC4419, Using the Adverse Event Scale: National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 (NCI CTCAE v4.0)</measure>
    <time_frame>First dose of IMRT through the completion of IMRT, estimated to be up to 7 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate and compare the safety of GC4419 of each respective arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Radiation Induced Severe Oral Mucositis per WHO Criteria, Through a Minimum of 60 Gy IMRT Delivered to the Tumor</measure>
    <time_frame>Minimum of 60 Gy administered to tumor, approximately 30 IMRT fractions, which is estimated to be 6-7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the effects of GC4419, administered at each of two daily doses vs. placebo, on the cumulative incidence of severe OM, defined as any occurrence of WHO Grade 3-4 OM, from the first IMRT fraction through the delivery of the 30th IMRT fraction (approximately 60 Gy delivered to tumor).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Severe Oral Mucositis, per WHO Criteria for Entire Course of IMRT</measure>
    <time_frame>First dose of IMRT through the completion of IMRT, estimated to be up to 6-7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the cumulative incidence of severe OM from the first IMRT fraction through the last IMRT fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Severe Oral Mucositis, per WHO Criteria</measure>
    <time_frame>Onset of Severe OM, estimated to be between first dose of IMRT and 7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the time to onset to severe OM: time (days), median IMRT dose delivered, and number of IMRT fractions delivered at onset of severe OM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Grade 4 Oral Mucositis, per WHO Criteria</measure>
    <time_frame>Onset of Grade 4 OM, estimated to be between first dose of IMRT and 7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the cumulative incidence of Grade 4 OM from the first IMRT fraction through the last IMRT fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Severe Oral Mucositis, Per WHO Criteria</measure>
    <time_frame>Duration of Severe OM, from first observation until resolution to Grade 2 or Less, estimated to be between first dose of IMRT and 15 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the duration of severe OM as assessed by the number of instances of severe OM of &gt;/= 7 days' duration, defined as time from observation of severe OM to the next subsequent observation of OM &gt;/= Grade 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GC4419's Effect on Tumor Response within 1 Year of IMRT Completion.</measure>
    <time_frame>Up to 1 year following completion of chemoradiation.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate and compare the effect of treatment assignment on tumor outcomes (locoregional failure, distant metastases, progression-free survival, overall survival).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>OM Incidence by Cumulative IMRT, Per WHO Criteria</measure>
    <time_frame>First Dose of IMRT through 8 weeks of post IMRT follow-up, or resolution to Grade 1 or less.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare OM incidence by cumulative IMRT from the first IMRT fraction through the end of post-IMRT early follow-up; post-IMRT early follow-up will extend for up to eight weeks post the last IMRT fraction administered or until a given patient's OM is WHO Grade 0 or 1.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative Severe OM Incidence at Cumulative Delivery of 20-29, 30-39, 40-49, or 50-59 Gy of IMRT, Per WHO Criteria</measure>
    <time_frame>First Dose of IMRT through 8 weeks of post IMRT follow-up, or resolution to Grade 1 or less.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare cumulative severe OM incidence at cumulative delivery of 20-29, 30-39, 40-49, or 50-59 Gy of IMRT</description>
  </other_outcome>
  <other_outcome>
    <measure>Areas Under the OM-Severity vs. Time Curves</measure>
    <time_frame>First Dose of IMRT through 8 weeks of post IMRT follow-up, or resolution to Grade 1 or less.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the areas under the OM-severity vs. time curves</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients with Severe OM, per WHO Criteria</measure>
    <time_frame>First Dose of IMRT through 8 weeks of post IMRT follow-up, or resolution to Grade 1 or less.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the number of patients with severe OM on more than one visit prior to week 6, visit 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Number of Days (Per Patient) of Severe OM, per WHO Criteria</measure>
    <time_frame>First Dose of IMRT through 8 weeks of post IMRT follow-up, or resolution to Grade 1 or less.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the total number of days (per patient) of severe OM though the end of IMRTon more than one visit prior to week 6, visit 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterize Effects of GC4419 on Ulcerative (≥ Grade 2) OM, per WHO Criteria</measure>
    <time_frame>First Dose of IMRT through 8 weeks of post IMRT follow-up, or resolution to Grade 1 or less.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the effects of GC4419 on the incidence, onset, and duration of ulcerative (≥ Grade 2) OM</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Effects of GC4419 on Chemoradiation Treatment Delays</measure>
    <time_frame>First dose of chemoradiation to last dose of chemoradiation, estimated to be between day 1 and up to 7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare treatment interruptions of chemoradiation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare the Adverse Event Rates of GC4419 Toxicities of Interest within Each Dosing Group: xerostomia, trismus, fatigue, weight loss, radiation dermatitis, and dysgeusia</measure>
    <time_frame>First Dose of IMRT, up to approximately 7 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate and compare the effects of GC4419 on other specific toxicities of interest associated with concurrent chemoradiation: xerostomia, trismus, fatigue, weight loss, radiation dermatitis, and dysgeusia (changes in taste).</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare the Results of Patient Reported Outcomes, Specifically the Oral Mucositis Daily Questionnaire within Each Dosing Group</measure>
    <time_frame>First Dose of IMRT, up to approximately 7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate and compare the effects of treatment on patient-reported outcomes as obtained using the Oral Mucositis Daily Questionnaire (OMDQ).</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of GC4419 on Narcotic Analgesic Requirements</measure>
    <time_frame>First Dose of IMRT through the last dose of IMRT, expected to be between first dose and 7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate and compare the use of narcotic analgesics by patients according to treatment assignment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of GC4419 on Gastronomy Tube Dependence</measure>
    <time_frame>Date of gastronomy tube placement through the date of removal, which is expected to be between and average of 7 days prior to starting IMRT and up to 15 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the requirement for use of gastrostomy tubes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare the Complication Rates of Indwelling Venous Access Devices Among All Dosing Groups</measure>
    <time_frame>Date of indwelling venous access devices through the date of removal, which is expected to be an average of up to 7 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate and compare the use and complications of indwelling venous access devices.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of GC4419 on Requirement for Unscheduled Hospitalizations</measure>
    <time_frame>First dose of chemoradiation through the last dose of chemoradiation, expected to be between day 1 and 7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate and compare the requirement for unscheduled hospitalizations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of GC4419 on Biologic Markers of Response</measure>
    <time_frame>First dose of IMRT through the last dose of IMRT, expected to be between day 1 and 7 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the effects of treatment assignment on biologic markers of response.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Radiation Induced Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>Low Dose GC4419: 30mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg GC4419/day prior to IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose GC4419: 90mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg GC4419/day prior to IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily, prior to IMRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose GC4419: 30mg/day</intervention_name>
    <description>Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).</description>
    <arm_group_label>Low Dose GC4419: 30mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose GC4419: 90mg/day</intervention_name>
    <description>High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).</description>
    <arm_group_label>High Dose GC4419: 90mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically-confirmed diagnosis of squamous cell carcinoma of the head and neck,
             defined as SCC of the oral cavity or oropharynx that will be treated with cisplatin
             plus concurrent IMRT Note: Patients with unknown primary tumors whose treatment plan
             matches the requirements specified in Inclusion Criteria #2 and #3 below are eligible
             for the trial.

          2. Treatment plan to receive a continuous course of IMRT delivered as single daily
             fractions of 2.0 to 2.2 Gy with a cumulative radiation dose between 60 Gy and 72 Gy.
             Planned radiation treatment fields must include at least two oral sites (buccal
             mucosa, floor of mouth, tongue, soft palate) that are each planned to receive a total
             of &gt; 50 Gy. Patients who have had prior surgery are eligible, provided they have
             fully recovered from surgery, and patients who may have surgery in the future are
             eligible.

          3. Treatment plan to receive standard cisplatin monotherapy administered either every
             three weeks (80-100 mg/m2 for 3 doses) or weekly (30-40 mg/m2 for 6-7 doses). The
             decision on which chemotherapy regimen to use in combination with IMRT and GC4419
             will be at the discretion of the investigator.

          4. Age 18 years or older

          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          6. Adequate hematologic function as indicated by:

               -  Absolute neutrophil counts (ANC) ≥ 1,500/mm3

               -  Hemoglobin (Hgb) ≥ 9.0 g/dL

               -  Platelet count ≥ 100,000/mm3

          7. Adequate renal and liver function as indicated by:

               -  Serum creatinine acceptable for treatment with cisplatin per institutional
                  guidelines

               -  Total bilirubin ≤ 1.5 x upper-normal limit (ULN)

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN

               -  Alkaline phosphatase ≤ 2.5 x ULN

          8. Human papilloma virus (HPV) status in tumor has been documented using tumor
             immunohistochemistry for HPV-p16 or other accepted test

          9. Serum pregnancy test negative for females of childbearing potential

         10. Males and females must agree to use effective contraception starting prior to the
             first day of treatment and continuing for 30 days after the last dose of GC4419

         11. Properly obtained written informed consent

        Exclusion Criteria:

          1. Tumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, or salivary glands

          2. Metastatic disease (Stage IV C)

          3. Prior radiotherapy to the region of the study cancer or adjacent anatomical sites or
             more than 25% of total body marrow-bearing area (potentially interfering with
             chemotolerance)

          4. Prior induction chemotherapy

          5. Receiving any approved or investigational anti-cancer agent other than those provided
             for in this study

          6. Participation in another clinical trial or use of another investigational agent
             within 30 days of study entry

          7. Requirement for significantly modified diet (liquids and/or solids) due to
             compromised oral/pharyngeal function at baseline

          8. Requirement at baseline for parenteral or gastrointestinal tube-delivered nutrition
             for any reason

          9. Malignant tumors other than HNC within the last 5 years, unless treated definitively
             and with low risk of recurrence in the judgment of the treating investigator

         10. Active infectious disease excluding oral candidiasis

         11. Presence of oral mucositis (WHO Score ≥ Grade 1) at study entry

         12. Known history of HIV or active hepatitis B/C (patients who have been vaccinated for
             hepatitis B and do not have a history of infection are eligible)

         13. Female patients who are pregnant or breastfeeding

         14. Known allergies or intolerance to cisplatin and similar platinum-containing compounds

         15. Requirement for concurrent treatment with nitrates or other drugs that may, in the
             judgment of the treating investigator, create a risk for a precipitous decrease in
             blood pressure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon T Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jon T Holmlund, MD</last_name>
    <phone>(610) 725-1500</phone>
    <email>jholmlund@galeratx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffrey M Brill, BS</last_name>
    <phone>(610) 725-1500</phone>
    <email>jbrill@galeratx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona, Banner Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Ford</last_name>
      <phone>520-626-6800</phone>
      <email>jamiel1@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Sun Yi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences- Winthrop P. Rockefeller Cancer Institute</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Allen, BA, CCRP</last_name>
      <phone>501-686-8274</phone>
      <email>KGAllen@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Omar Atiq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pasco Pinellas Cancer Center</name>
      <address>
        <city>Holiday</city>
        <state>Florida</state>
        <zip>34691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Kisko, RN, BSN, ONC</last_name>
      <phone>727-849-8036</phone>
      <email>dkisko@tampabay.rr.com</email>
    </contact>
    <investigator>
      <last_name>Robert A Araujo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Health Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Stewart, PhD, RN, ONC</last_name>
      <phone>863-904-1877</phone>
      <email>robin.stewart@myLRH.org</email>
    </contact>
    <investigator>
      <last_name>Madhavi Venigalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Health Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Miles, RN</last_name>
      <phone>321-841-7607</phone>
      <email>Erin.miles@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Oncology Group</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walid Kara</last_name>
      <phone>850-416-6316</phone>
      <email>walid.kara@shhpens.org</email>
    </contact>
    <investigator>
      <last_name>Gerald Lowrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Indianan, Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Sivicek, RN</last_name>
      <phone>574-364-2359</phone>
      <email>hsivicek@goshenhealth.com</email>
    </contact>
    <investigator>
      <last_name>James Wheeler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Logan Ahmann</last_name>
      <phone>319-356-7611</phone>
      <email>Logan-ahmann@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Carryn Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Albert B. Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Moore, RN, BSN</last_name>
      <phone>859-323-0532</phone>
      <email>colleenmoore@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Mahesh Kudrimoti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital, James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Roberts</last_name>
      <phone>502-333-6934</phone>
      <email>Teresa.roberts@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Neil Dunlap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Schumpert Cancer Treatment Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Powell, RN, BSN</last_name>
      <phone>318-681-6007</phone>
      <email>jennifer.powell@christushealth.org</email>
    </contact>
    <investigator>
      <last_name>Scott Boniol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Regional Cancer Program</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Lopez, CCRP</last_name>
      <phone>413-794-4154</phone>
      <email>Betzaida.lopez@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Wilson Mertens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Kempf</last_name>
      <phone>734-615-1749</phone>
      <email>kempfl@med.mich.edu</email>
    </contact>
    <investigator>
      <last_name>Francis Worden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ellis Fichel Cancer Center, University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Walker</last_name>
      <phone>573-884-0053</phone>
      <email>wallera@health.missouri.edu</email>
    </contact>
    <investigator>
      <last_name>C. Daniel Kingsley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunterdon Hematology Oncology, LLC Hunterdon Regional Cancer Center</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Bower</last_name>
      <phone>908-237-2330</phone>
      <phone_ext>3</phone_ext>
      <email>Bower.kaitlyn@hunterdonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Waqas Rehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juhi Purswani</last_name>
      <phone>914-484-0120</phone>
      <email>jpurswan@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Madhar Garg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University, Leo W. Jenkins Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Peaden, RN</last_name>
      <phone>252-737-7079</phone>
      <email>peadend@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Gordon, DDS MPH PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marion L. Shepard Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>North Carolina</state>
        <zip>27889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Alligood, RN, OCN</last_name>
      <phone>252-974-9389</phone>
      <email>Kristy.alligood@vidanthealth.com</email>
    </contact>
    <investigator>
      <last_name>John J Inzerillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scarlett Hutchens</last_name>
      <phone>336-713-6915</phone>
      <email>snhutche@WakeHealth.edu</email>
    </contact>
    <investigator>
      <last_name>Marcello Bonomi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University, James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Vetter</last_name>
      <phone>614-293-6641</phone>
      <email>Sara.Vetter@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Dukagjin Blakaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Ciesler, MS</last_name>
      <phone>419-794-7720</phone>
      <phone_ext>3103</phone_ext>
      <email>jciesler@toledoclinic.com</email>
    </contact>
    <investigator>
      <last_name>Rex Mowat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Minger, CCRC</last_name>
      <phone>503-494-8756</phone>
      <email>mingerj@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>John Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Avalos</last_name>
      <phone>503-721-1433</phone>
      <email>Kathy.avalos@va.gov</email>
    </contact>
    <investigator>
      <last_name>Ronald J Maggiore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie Dancho, RN, ONC</last_name>
      <phone>484-503-4150</phone>
      <email>Stacie.dancho@sluhn.org</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Agarwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas-Jefferson University Hospital-Bodine Center for Cancer Treatment</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Weller</last_name>
      <phone>214-955-8619</phone>
      <email>Kimberly.weller@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Voichita Bar-Ad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital, Allegheny Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Flannery, RN</last_name>
      <phone>412-359-8379</phone>
      <email>gflanner@wpahs.org</email>
    </contact>
    <investigator>
      <last_name>Larissa Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Luppe, RN</last_name>
      <phone>401-444-5014</phone>
      <email>dluppe@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Ariel Birnbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Hanselman, RN</last_name>
      <phone>864-560-1053</phone>
      <email>lhanselman@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Amarintha Curtis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Lakes Health Care System</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darcy Raethz, RN, ONC</last_name>
      <phone>605-882-6803</phone>
      <email>darcy.raethz@prairielakes.com</email>
    </contact>
    <investigator>
      <last_name>Bipinkumar Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mountain States Health Alliance</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>36704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nonna Stepanov, MD, CCRC</last_name>
      <phone>423-431-5654</phone>
      <email>stepanovnv@msha.com</email>
    </contact>
    <investigator>
      <last_name>Kyle Colvett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Allan</last_name>
      <phone>865-305-5483</phone>
      <email>rkallan@mc.utmck.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Kelley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Beasley, RN, CRC</last_name>
      <phone>469-467-4340</phone>
      <email>stacey.beasley@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mark Engleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tyler Hematology Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Nance, RN</last_name>
      <phone>903-592-6152</phone>
      <email>anance@thodocs.com</email>
    </contact>
    <investigator>
      <last_name>Arielle Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Lyon, RN</last_name>
      <phone>425-297-5531</phone>
      <email>katie.lyon@providence.org</email>
    </contact>
    <investigator>
      <last_name>William Wisbeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannine Barton</last_name>
      <phone>206-277-3101</phone>
      <email>Jeannine.barton@va.gov</email>
    </contact>
    <investigator>
      <last_name>Tony Quang, MD, JD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Miller, RN, OCN</last_name>
      <phone>509-228-1689</phone>
      <email>Rose.Miller@ccnw.net</email>
    </contact>
    <investigator>
      <last_name>Christopher Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 2, 2016</lastchanged_date>
  <firstreceived_date>July 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma of the head and neck</keyword>
  <keyword>oral cavity</keyword>
  <keyword>oropharynx</keyword>
  <keyword>intensity-modulated radiation therapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>oral mucositis</keyword>
  <keyword>superoxide dismutase</keyword>
  <keyword>radioprotection</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
